{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:19:19Z","timestamp":1793787559772,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.11.026","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:20:29Z","timestamp":1763346029000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"Delaney Bake","family":"Stratton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anngela Christina","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise J.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Curiel-Lewandrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2025.11.026_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.11.026_bib2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jamadermatol.2020.3677","article-title":"Incidence of multiple vs first cutaneous squamous cell carcinoma on a nationwide scale and estimation of future incidences of cutaneous squamous cell carcinoma","volume":"156","author":"Tokez","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.026_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.11.026_bib4","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jid.2017.06.025","article-title":"Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study","volume":"137","author":"Eigentler","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.026_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011","volume":"48","author":"Guy","year":"2015","journal-title":"Am J Prev Med"},{"issue":"11","key":"10.1016\/j.jaad.2025.11.026_bib6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2015.1702","article-title":"Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study","volume":"151","author":"Levine","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.11.026_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamadermatol.2020.1988","article-title":"Assessment of cutaneous squamous cell carcinoma (cSCC) in situ incidence and the risk of developing invasive cSCC in patients with prior cSCC in situ vs the general population in the Netherlands, 1989-2017","volume":"156","author":"Tokez","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.11.026_bib8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the American Joint Committee on cancer staging manual, 8th edition vs the Brigham and Women's Hospital tumor classification system for cutaneous squamous cell carcinoma","volume":"155","author":"Ruiz","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.026_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1708701","article-title":"Update on keratinocyte carcinomas","volume":"379","author":"Nehal","year":"2018","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2025.11.026_bib10","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/DSS.0000000000002409","article-title":"Incidence of surgical site infections in second intention healing after dermatologic surgery","volume":"46","author":"Schimmel","year":"2020","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.026_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/cancers16010158","article-title":"Intralesional treatments for invasive cutaneous squamous cell carcinoma","volume":"16","author":"Baeza-Hernandez","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.026_bib12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","article-title":"Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas","volume":"84","author":"Maxfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"25","key":"10.1016\/j.jaad.2025.11.026_bib13","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.026_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.026_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.026_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.026_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/DSS.0000000000002739","article-title":"Complete and sustained remission of metastatic cutaneous squamous cell carcinoma in a liver transplant patient treated with talimogene laherparepvec","volume":"47","author":"Nguyen","year":"2021","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.026_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000530851","article-title":"Use of talimogene laherparepvec to treat cutaneous squamous cell carcinoma in a renal transplant patient","volume":"15","author":"Miller","year":"2023","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2025.11.026_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdcr.2023.07.033","article-title":"Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec","volume":"40","author":"Lebhar","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.026_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"S2","key":"10.1016\/j.jaad.2025.11.026_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.33594\/000000433","article-title":"Oh, the mutations you'll acquire! A systematic overview of cutaneous squamous cell carcinoma","volume":"55","author":"Droll","year":"2021","journal-title":"Cell Physiol Biochem"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.11.026_bib23","first-page":"A157","article-title":"137 Majority of mutations in cutaneous squamous cell carcinoma are unique to individual tumors","volume":"11","author":"Borden","year":"2023","journal-title":"J Immunotherap Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:35:34Z","timestamp":1771392934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0190962225032244"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.026","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}